Neutra Corp. (NTRR) CEO Sydney Jim Discusses Pain
Post# of 70
(Total Views: 258)
Posted On: 09/04/2019 4:27:49 PM
Neutra Corp. (NTRR) CEO Sydney Jim Discusses Pain Management, CBD Purity and Becoming Vertically Integrated in the Hemp Industry
- The company’s CEO discussed NTRR’s strategic acquisition of hemp retail brand Vivis and hemp cultivator J3 Holdings
- Neutra Corp. plans to finish building and lab improvements to J3 Holdings in 2019
- The company’s focus is on CBD as an option to treat types of chronic pain
- CBD sales in the U.S. are projected to exceed $20 billion by 2024
Texas-based Neutra Corp. (OTCQB: NTRR) is expanding into hemp cultivation and purified hemp extract products. Its CEO, Sydney Jim, discussed the company’s operations and objectives in an exclusive interview with NetworkNewsWire (http://nnw.fm/7wSXR). Jim, a former professional tennis player, emphasized the company’s motivation to help the next generation of athletes with pain management. During the interview, he talks about dealing with pain, not only as a former professional athlete but, on an occasion as recent as last year, when he suffered multiple severe injuries and broken bones as a result of an accident.
Jim knows the benefits of hemp-based products first-hand, and CBD may offer an option for treating different types of chronic pain. A study cited by Harvard University showed that CBD applied on the skin could help lower pain and inflammation due to arthritis (http://nnw.fm/FaE7x). Other research demonstrated the mechanism by which CBD inhibits inflammatory and neuropathic pain – two of the most difficult types of chronic pain to treat.
Neutra Corp.’s goal in 2019 is to become vertically involved in the hemp market, from cultivation to formulation of products and distribution for retail sales in an ever-growing market. Leading cannabis researchers BDS Analytics and Arcview Market Research project that the collective market for CBD sales in the U.S. will surpass $20 billion by 2024, forecasting a 49 percent compound annual growth rate across all distribution channels (http://nnw.fm/jCSO8).
Neutra’s interests go above and beyond profit. “Most of our focus, obviously, is in our quality and potency of our products, because there is a vast difference between very cheap products and quality products,” Jim said in the interview. It takes a lot of time to extract CBD and make sure only the best quality is made available, which is why those particular products are relatively expensive, Neutra Corp.’s CEO added.
Jim also talked about the company’s strategic acquisition of Vivis, a hemp retail brand with which the Neutra CEO has personally worked. Vivis’ extracts are certified by a third-party lab to ensure their quality. Each Vivis product comes with a certificate of analysis as proof of quality, Jim explained.
Neutra Corp. also aims to finish the building and lab improvements of hemp cultivator J3 Holdings, for which the company recently submitted a letter of intent. J3 Holdings owns a lot of land where hemp can be cultivated, as well as a warehouse – assets that are expected to increase Neutra Corp.’s value. In September, Neutra Corp. plans to “finalize the equipment going in there (J3 Holdings) and wrap the financing up to hit the ground running in 2020.”
On a final note, the company’s CEO expressed his hope of bringing Vivis and J3 together to strengthen Neutra’s market infiltration while helping it become a vertically integrated company with both a strong market presence and an established brand that’s known for the superiority of its product and its commitment to quality.
For more information, visit the company’s website at www.NeutraInc.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- The company’s CEO discussed NTRR’s strategic acquisition of hemp retail brand Vivis and hemp cultivator J3 Holdings
- Neutra Corp. plans to finish building and lab improvements to J3 Holdings in 2019
- The company’s focus is on CBD as an option to treat types of chronic pain
- CBD sales in the U.S. are projected to exceed $20 billion by 2024
Texas-based Neutra Corp. (OTCQB: NTRR) is expanding into hemp cultivation and purified hemp extract products. Its CEO, Sydney Jim, discussed the company’s operations and objectives in an exclusive interview with NetworkNewsWire (http://nnw.fm/7wSXR). Jim, a former professional tennis player, emphasized the company’s motivation to help the next generation of athletes with pain management. During the interview, he talks about dealing with pain, not only as a former professional athlete but, on an occasion as recent as last year, when he suffered multiple severe injuries and broken bones as a result of an accident.
Jim knows the benefits of hemp-based products first-hand, and CBD may offer an option for treating different types of chronic pain. A study cited by Harvard University showed that CBD applied on the skin could help lower pain and inflammation due to arthritis (http://nnw.fm/FaE7x). Other research demonstrated the mechanism by which CBD inhibits inflammatory and neuropathic pain – two of the most difficult types of chronic pain to treat.
Neutra Corp.’s goal in 2019 is to become vertically involved in the hemp market, from cultivation to formulation of products and distribution for retail sales in an ever-growing market. Leading cannabis researchers BDS Analytics and Arcview Market Research project that the collective market for CBD sales in the U.S. will surpass $20 billion by 2024, forecasting a 49 percent compound annual growth rate across all distribution channels (http://nnw.fm/jCSO8).
Neutra’s interests go above and beyond profit. “Most of our focus, obviously, is in our quality and potency of our products, because there is a vast difference between very cheap products and quality products,” Jim said in the interview. It takes a lot of time to extract CBD and make sure only the best quality is made available, which is why those particular products are relatively expensive, Neutra Corp.’s CEO added.
Jim also talked about the company’s strategic acquisition of Vivis, a hemp retail brand with which the Neutra CEO has personally worked. Vivis’ extracts are certified by a third-party lab to ensure their quality. Each Vivis product comes with a certificate of analysis as proof of quality, Jim explained.
Neutra Corp. also aims to finish the building and lab improvements of hemp cultivator J3 Holdings, for which the company recently submitted a letter of intent. J3 Holdings owns a lot of land where hemp can be cultivated, as well as a warehouse – assets that are expected to increase Neutra Corp.’s value. In September, Neutra Corp. plans to “finalize the equipment going in there (J3 Holdings) and wrap the financing up to hit the ground running in 2020.”
On a final note, the company’s CEO expressed his hope of bringing Vivis and J3 together to strengthen Neutra’s market infiltration while helping it become a vertically integrated company with both a strong market presence and an established brand that’s known for the superiority of its product and its commitment to quality.
For more information, visit the company’s website at www.NeutraInc.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Neutra Corp (NTRR) Stock Research Links
Scroll down for more posts ▼